Evidence map›Paper›PMID 23489578›Full record

ArticleExperimental dermatology2013

There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis.

Rolf K Swoboda, Meenhard Herlyn

Open access · bronzeAbstract read
In one paragraph

Article in Experimental dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. MicroRNA heterogeneity in melanoma progression.Seminars in cancer biology · 2019
    Review
  2. Article
  3. Pseudogenes in Human Cancer.Frontiers in medicine · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rolf K SwobodaThe Wistar Institute, Philadelphia, PA 19104, USA.
Meenhard Herlyn
The Wistar Institute · US

Funding

TUMOR DEVELOPMENT AND PROGRESSION IN HUMAN MELANOCYTESP01CA025874 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1985 to 2015
$19.0M
CELL/CELL COMMUNICATION DURING MELANOMA PROGRESSIONR01CA076674 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1998 to 2015
$4.0M
METASTATIS: BIOLOGICAL PHENOTYPE AND MODELS FOR THERAPYR01CA047159 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 1989 to 2015
$3.9M
NCI NIH HHS CA025874NCI NIH HHS CA047159NCI NIH HHS CA076674NCI NIH HHS P01 CA025874NCI NIH HHS R01 CA047159NCI NIH HHS R01 CA076674
6 · The paper itself

Abstract

Until recently, the general perception has been that mutations in protein-coding genes are responsible for tumorigenesis. With the discovery of (V600E)BRAF in about 50% of cutaneous melanomas, there was an increased effort to find additional mutations. However, mutations characterized in melanoma to date cannot account for the development of all melanomas. With the discovery of microRNAs as important players in melanomagenesis, protein mutations are no longer considered the sole drivers of tumors. Recent research findings have expanded the view for tumor initiation and progression to additional non-coding RNAs. The data suggest that tumorigenesis is likely an interplay between mutated proteins and deregulation of non-coding RNAs in the cell with an additional role of the tumor environment. With the exception of microRNAs, our knowledge of the role of non-coding RNAs in melanoma is in its infancy. Using few examples, we will summarize some of the roles of non-coding RNAs in tumorigenesis. Thus, there is a whole world beyond protein-coding sequences and microRNAs, which can cause melanoma.

Indexed as

Alternative SplicingEpigenesis, GeneticHumansMelanomaMicroRNAsMutationRNA, UntranslatedSkin NeoplasmsMicroRNAsRNA, Untranslated

Identifiers

PMID23489578
PMCPMC3637432
OpenAlexW1986996709

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.